Ustekinumab: new option for moderate‐to‐severe psoriasis

Ustekinumab (Stelara), a novel biologic for the treatment of moderate‐to‐severe plaque psoriasis, targets interleukins rather than TNF‐alpha. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Dr Downs discusses its place in psoriasis treatment. Copyright © 2009 Wiley Interface Ltd